187 related articles for article (PubMed ID: 18245464)
1. Multiple alternative splicing markers for ovarian cancer.
Klinck R; Bramard A; Inkel L; Dufresne-Martin G; Gervais-Bird J; Madden R; Paquet ER; Koh C; Venables JP; Prinos P; Jilaveanu-Pelmus M; Wellinger R; Rancourt C; Chabot B; Abou Elela S
Cancer Res; 2008 Feb; 68(3):657-63. PubMed ID: 18245464
[TBL] [Abstract][Full Text] [Related]
2. Identification of alternative splicing markers for breast cancer.
Venables JP; Klinck R; Bramard A; Inkel L; Dufresne-Martin G; Koh C; Gervais-Bird J; Lapointe E; Froehlich U; Durand M; Gendron D; Brosseau JP; Thibault P; Lucier JF; Tremblay K; Prinos P; Wellinger RJ; Chabot B; Rancourt C; Elela SA
Cancer Res; 2008 Nov; 68(22):9525-31. PubMed ID: 19010929
[TBL] [Abstract][Full Text] [Related]
3. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array.
Gardina PJ; Clark TA; Shimada B; Staples MK; Yang Q; Veitch J; Schweitzer A; Awad T; Sugnet C; Dee S; Davies C; Williams A; Turpaz Y
BMC Genomics; 2006 Dec; 7():325. PubMed ID: 17192196
[TBL] [Abstract][Full Text] [Related]
4. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer.
Wang Z; Lo HS; Yang H; Gere S; Hu Y; Buetow KH; Lee MP
Cancer Res; 2003 Feb; 63(3):655-7. PubMed ID: 12566310
[TBL] [Abstract][Full Text] [Related]
5. Expression of splicing factors in human ovarian cancer.
Fischer DC; Noack K; Runnebaum IB; Watermann DO; Kieback DG; Stamm S; Stickeler E
Oncol Rep; 2004 May; 11(5):1085-90. PubMed ID: 15069551
[TBL] [Abstract][Full Text] [Related]
6. Two-dimensional transcriptome profiling: identification of messenger RNA isoform signatures in prostate cancer from archived paraffin-embedded cancer specimens.
Li HR; Wang-Rodriguez J; Nair TM; Yeakley JM; Kwon YS; Bibikova M; Zheng C; Zhou L; Zhang K; Downs T; Fu XD; Fan JB
Cancer Res; 2006 Apr; 66(8):4079-88. PubMed ID: 16618727
[TBL] [Abstract][Full Text] [Related]
7. Alternative splicing in cancer: noise, functional, or systematic?
Skotheim RI; Nees M
Int J Biochem Cell Biol; 2007; 39(7-8):1432-49. PubMed ID: 17416541
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide detection of testis- and testicular cancer-specific alternative splicing.
He C; Zuo Z; Chen H; Zhang L; Zhou F; Cheng H; Zhou R
Carcinogenesis; 2007 Dec; 28(12):2484-90. PubMed ID: 17724370
[TBL] [Abstract][Full Text] [Related]
9. Screening for genes associated with ovarian cancer prognosis.
Chang XH; Zhang L; Yang R; Feng J; Cheng YX; Cheng HY; Ye X; Fu TY; Cui H
Chin Med J (Engl); 2009 May; 122(10):1167-72. PubMed ID: 19493465
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K
Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012
[TBL] [Abstract][Full Text] [Related]
11. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene.
Bonnet C; Krieger S; Vezain M; Rousselin A; Tournier I; Martins A; Berthet P; Chevrier A; Dugast C; Layet V; Rossi A; Lidereau R; Frébourg T; Hardouin A; Tosi M
J Med Genet; 2008 Jul; 45(7):438-46. PubMed ID: 18424508
[TBL] [Abstract][Full Text] [Related]
12. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
[TBL] [Abstract][Full Text] [Related]
13. Identification of candidates for tumor-specific alternative splicing in the thyroid.
Guimarães GS; Latini FR; Camacho CP; Maciel RM; Dias-Neto E; Cerutti JM
Genes Chromosomes Cancer; 2006 Jun; 45(6):540-53. PubMed ID: 16493598
[TBL] [Abstract][Full Text] [Related]
14. BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer.
Le Page C; Ouellet V; Quinn MC; Tonin PN; Provencher DM; Mes-Masson AM
Cancer Epidemiol Biomarkers Prev; 2008 Apr; 17(4):913-20. PubMed ID: 18398031
[TBL] [Abstract][Full Text] [Related]
15. Changes of the alternative splicing variants of human telomerase reverse transcriptase during gastric carcinogenesis.
Xu JH; Wang YC; Geng X; Li YY; Zhang WM
Pathobiology; 2009; 76(1):23-9. PubMed ID: 19188747
[TBL] [Abstract][Full Text] [Related]
16. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H
Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951
[TBL] [Abstract][Full Text] [Related]
17. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
18. E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomas.
De Meyer T; Bijsmans IT; Van de Vijver KK; Bekaert S; Oosting J; Van Criekinge W; van Engeland M; Sieben NL
J Pathol; 2009 Jan; 217(1):14-20. PubMed ID: 18991331
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatics detection of alternative splicing.
Kim N; Lee C
Methods Mol Biol; 2008; 452():179-97. PubMed ID: 18566765
[TBL] [Abstract][Full Text] [Related]
20. Data analysis of alternative splicing microarrays.
Cuperlovic-Culf M; Belacel N; Culf AS; Ouellette RJ
Drug Discov Today; 2006 Nov; 11(21-22):983-90. PubMed ID: 17055407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
